|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and more than 2,300 generic ingredients from more than 1,700 branded and generic pharmaceutical companies, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: ALLEGRA
Summary for Tradename: ALLEGRA
|
| |||||||||
Clinical Trials for: ALLEGRABioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions Status: Completed Condition: Healthy Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions Status: Completed Condition: Healthy Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions Status: Completed Condition: Healthy Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr.Reddy's Under Fed Conditions Status: Completed Condition: Healthy Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)(COMPLETED) Status: Completed Condition: Seasonal Allergic Rhinitis Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)(COMPLETED) Status: Completed Condition: Seasonal Allergic Rhinitis Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)(COMPLETED) Status: Completed Condition: Seasonal Allergic Rhinitis Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis Status: Completed Condition: Rhinitis Seasonal Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg Status: Completed Condition: Healthy Food Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg Status: Completed Condition: Healthy Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | ALLEGRA | fexofenadine hydrochloride | CAPSULE; ORAL | 020625 | Jul 25, 1996 | DISCN | No | 5,578,610*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | ALLEGRA | fexofenadine hydrochloride | CAPSULE; ORAL | 020625 | Jul 25, 1996 | DISCN | No | 5,738,872*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | ALLEGRA | fexofenadine hydrochloride | CAPSULE; ORAL | 020625 | Jul 25, 1996 | DISCN | No | 5,855,912*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | ALLEGRA | fexofenadine hydrochloride | CAPSULE; ORAL | 020625 | Jul 25, 1996 | DISCN | No | 5,932,247*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: ALLEGRA
| Drugname | Dosage | Strength | RLD | Submissiondate |
| fexofenadine hydrochloride | Oral Suspension | 30 mg/5 mL | Allegra | 1/25/2010 |
| fexofenadine hydrochloride and pseudoephedrine hydrochloride | Extended-release Tablets | 180 mg/240 mg | Allegra-D 24 Hour | 6/6/2007 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc